Vinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.x
Untitled Document

References:

Andolex

1. Impact RX November 2015 (Constructed Market).

2. Almazan NA. Benzydamine HCl 0.15 % for oropharyngeal diseases and surgeries: A review of clinical trials. Philip Scientific J 2009;42(1):37-42.

3. Keijser J, et al. Comparison of 2 commercially available chlorhexidine mouthrinses. J Periodontol 2003;74(2):214-8.

4. Simard-Savoie S, et al. Topical anaesthetic activity of benzydamine. Curr Ther Res 1978;23(6):634-745.

5. IMS Total Private Market Value MAT. November 2015. (R02A. Pharyngeal Preparations).

6. Quane PA, et al. Pharmacology of benzydamine. Inflammopharmacology 1998;6:95-107.

7. Modéer T, et al. Benzydamine reduces prostaglandin production in human gingival fibroblasts challenged with interleukin-1 b or tumor nerosis factor a. Acta Odontol Scand 1999;57(1):40-45.

8. Cioli V, et al. Review of pharmacological data on benzydamine. Int J Tlss Reac 1985;VII(3):205-213.

9. Turnbull RS. Benzydamine Hydrochloride (Tantum) In the management of oral inflammatory conditions. J Can Dent Assoc 1995;61(2):127-134.

10. White SK. The pharmacology of benzydamine. Res Clin Forums 1988;10(8):9-23.

Scheduling status: S1 Proprietary name (and dosage form): ANDOLEX LOZENGES. Composition: Each lozenge contains: Benzydamine HCl 3.00 mg. Registration number: 31/16/0239. [Act 101/1965] Scheduling status: S1 Proprietary name (and dosage form): ANDOLEX Solution. Composition: Each 15 mL contains Benzydamine HCI 22.5 mg. Preservative: Methyl hydroxybenzoate 0.1% m/v. Contains alcohol 10%v/v. Registration number: Z/16/40. [Act 101/1965] Scheduling status: S1 Proprietary name (and dosage form): ANDOLEX-C Oral Rinse. Composition: Each 15 mL contains: Benzydamine HCI 22.5 mg, Chlorhexidine gluconate 18 mg, Alcohol 9% v/v. Registration number: 31/16.4/0143. [Act 101/1965] Scheduling status: S1 Proprietary name (and dosage form): ANDOLEX-C LOZENGES HONEY LEMON. Composition: Each lozenge contains: Benzydamine HCI 3.00 mg, Cetylpyridinium chloride 1.33 mg. Registration number: 35/16.4/0320. [Act 101/1965] Scheduling status: S1 Proprietary name (and dosage form): ANDOLEX-C LOZENGES ORANGE. Composition: Each lozenge contains: Benzydamine HCI 3.00 mg, Cetylpyridinium chloride 1.33 mg. Registration number: 36/16.4/0195. [Act 101/1965] Scheduling status: S1Proprietary name (and dosage form): ANDOLEX-C LOZENGES EUCALYPTUS MENTHOL. Composition: Each loz enge contains: Benzydamine HCl 3.00 mg. Cetylpyridinium chloride 1.33 mg. Registration number: 33/16.4/0374. [Act 101/1965] Scheduling status: S1 Proprietary name (and dosage form): ANDOLEX-C LOZENGES. Composition: Each lozenge contains: Benzydamine HCl 3.00 mg, Cetylpyridinium chloride 1.33 mg.Registration number: 31/16.4/0042. [Act 101/1965] Scheduling status:S1 Proprietary name (and dosage form): ANDOLEX-C ORAL GEL. Composition: Benzydamine HCI 10 mg/g, Cetylpyridinium Chloride 1 mg/g.  For full prescribing information, refer to the individual package insert(s) approved by the medicines regulatory authority.  Further information is available on request from iNova Pharmaceuticals.

Allerguard

1. Allerguard Package Insert. July 2016.

Proprietary name (and dosage form): Allerguard Allergy Nasal Spray. Marketed by: iNova Pharmaceuticals (Pty) Ltd. Reg.No.: 1952/001640/07. 15E Riley Road, Bedfordview, Gauteng, South Africa, 2007. Tel. No.: 011 087 0000 www.inovapharma.co.za. For full prescribing information, refer to the package insert. Further information available at www.allerguard.co.za or on request from iNova Pharmaceuticals.

Dry eye banner

Reference: 1. Impact Rx. Script data – May 2015.

Scheduling status: S0 Proprietary name and dosage form: Bausch & Lomb Moisture Drops eye drops. Composition: Each ml contains: Potassium chloride 3,5 mg and sodium chloride 4,0 mg, benzalkonium chloride 0,01 % m/v (preservative). Pharmacological classification: A34 other. Indications: For the temporary relief of burning and irritation caused by dryness of the eye. Registration number: 28/34/0013. Applicant: iNova Pharmaceuticals (Pty) Ltd, Co. Reg. No. 1952/001640/07, 15E Riley Road, Bedfordview Tel: 011 087 000. Scheduling status: S0 Proprietary name and dosage form: Ocuvite Complete soft gel casules. Composition: Each soft gel capsule contains fish oil rich in DHA 507,7 mg: of which DHA 180 mg and total omega-3_300mg, Lutein 5 mg, zeaxanthin 1 mg, vitamin C 90 mg, vitamin E 15 mg, zinc 7,5 mg. Applicant: iNova Pharmaceuticals (Pty) Ltd, Co. Reg. No. 1952/001640/07, 15E Riley Road, Bedfordview Tel: 011 087 000.
Scheduling status: S0 Proprietary name and dosage form: Liposic Eye Gel. Composition: Each 1 g contains: 2 mg carbomer, triglycerides – medium chain, sorbitol, sodium hydroxide and purified water, Cetrimide 0,01 % m/m (preservative). Pharmacological classification: A 15.4 Ophthalmic preparations - Other. Indications: Substitution of tear fluid for management of dry eye conditions such as symptomatic treatment of keratoconjunctivitis sicca.
Registration number: 37/15.4/0224. Applicant: iNova Pharmaceuticals (Pty) Ltd, Co. Reg. No. 1952/001640/07, 15E Riley Road, Bedfordview Tel: 011 087 000.

© 2003 Bausch & Lomb Incorporated. ®/™ denote trademarks of Bausch & Lomb Incorporated. Marketed by: Bausch & Lomb (SA) (Pty) Ltd. Reg. No.: 1996/003931/07. 15E Riley Road, Bedfordview, Gauteng, South Africa, 2008. Tel: +27 11 087 0000 www.bausch.co.za BL98/15



ReNu banner

*For full prescribing information, refer to the individual package inserts as approved by the medicines control council. Further details is available on request from SofLens (Pty) Ltd.

Reference: 1. Data on file. EUROMCONTACT, MAT Q4 2015 vs MAT Q4 2014.

Scheduling status: S0 Bausch & Lomb ReNu® Multi-Purpose Solution. Reg. No.: X/34/239. Each ml contains: Polyaminopropyl biguanide (Dymed™) 0.0005 mg, Disodium edetate 0.11 % m/v (Preservative).
Scheduling status: S0 Bausch & Lomb ReNu MultiPlus® Solution. Reg. No.: 33/34/0484. Each ml contains: Polyaminopropyl biguanide (Dymed™) 0.0010 mg, Hydroxyalkylphosphonate 0.30 mg, Disodium edetate (preservative) 0,11 % m/v. Applicant: iNova Pharmaceuticals (Pty) Ltd, Co. Reg. No. 1952/001640/07, 15E Riley Road, Bedfordview Tel: 011 087 000. Marketed by: Bausch & Lomb (SA) (Pty) Ltd. Reg. No.: 1996/003931/07. 15E Riley Road, Bedfordview, 2008, South Africa. Tel: +27 11 087 0000 www.bausch.co.za BL81/15

Biotrue solution banner

*Based on a U.S. patient satisfaction study.
Reference: 1. Reindel W, et al. Meta-analysis of the ocular biocompatibility of a new multipurpose lens care system. Clin Ophthalmol. 2013;7:2051-6.
© 2011 Bausch & Lomb Incorporated. ®/™ denote trademarks of Bausch & Lomb Incorporated. Marketed by: Bausch & Lomb (SA) (Pty) Ltd. Reg. No.: 1996/003931/07. 15E Riley Road, Bedfordview, 2008, South Africa. Tel: +27 11 087 0000 www.bausch.co.za BL81/15

Liposic banner

Reference: 1. Liposic Product Monograph. Data on file, Bausch&Lomb Inc.
Scheduling status: S0 Proprietary name and dosage form: Liposic Eye Gel. Composition: Each 1 g contains: 2 mg carbomer, triglycerides – medium chain, sorbitol, sodium hydroxide and purified water, Cetrimide 0,01 % m/m (preservative). Pharmacological classification: A 15.4 Ophthalmic preparations - Other. Indications: Substitution of tear fluid for management of dry eye conditions such as symptomatic treatment of keratoconjunctivitis sicca. Registration number: 37/15.4/0224.© 2003 Bausch & Lomb Incorporated. ®/™ denote trademarks of Bausch & Lomb Incorporated. Applicant: iNova Pharmaceuticals (Pty) Ltd, Co. Reg. No. 1952/001640/07, 15E Riley Road, Bedfordview Tel: 011 087 000. Marketed by: Bausch & Lomb (SA) (Pty) Ltd. Reg. No.: 1996/003931/07. 15E Riley Road, Bedfordview, Gauteng, South Africa, 2008. Tel: +27 11 087 0000 www.bausch.co.za BL94/15

footer

Inova logo